A recent study on the type 2 diabetes medication dapagliflozin has demonstrated its significant ability to reduce heart failure risk, particularly among individuals carrying inherited cardiomyopathy variants. The trial, which followed 12,685 adults with diabetes for 4.2 years, observed a 32% decrease in heart failure hospitalizations among non-carriers of these variants. However, the reduction was substantially higher, around 80%, in variant carriers. These findings underscore the potential for integrating genetic screening into proactive heart failure prevention, enabling the use of targeted therapies like dapagliflozin for early intervention in at-risk populations, although further research is required for non-diabetic individuals with these genetic predispositions.